• How to value the big four ASX banks

    maginfying glass over dollar sign

    Yesterday, I explored how some of the current issues facing the ASX banks could be impacting their ‘bankability’. But to understand how banks are valued in the first place, you need to recognise how they differ from other type of stocks. For example, unlike regular industrial stocks, banks make money from borrowing, lending and aiding the flow of money throughout the economy. This makes them highly vulnerable to the economic cycle, and as an investor you need to know when they’re out of the money.

    You need to tread carefully when using a price-to-earnings ratio (P/E) and dividend yield to gauge how attractive ASX bank shares might be. That’s because bad debts or one-off items can compromise the sustainability of bank dividends, as shareholders discovered in 2007 when they were slashed to help prop up badly needed bank capital.

    It’s also important to understand that banks require some peculiar evaluation criteria when it comes to assessing their intrinsic value and business performance. If you do want to use the P/E ratio to help value and compare one bank share against another, then it must be used alongside some bank-specific financial ratios.

    While some valuation principles are equally applicable to all companies, there are a number of complications specific to banks. These include determining leverage – due to being both borrower and lender – regulatory impact, capital expenditure and interest margins.

    Key ratios

    Net interest margin (NIM): A bank’s primary income source is the difference between the interest income from its loan book, and interest paid out to depositors. Typically expressed as a percentage of the average loans outstanding over the period under review, this is known as the ‘net interest margin’ (NIM). A high ratio indicates bank efficiency. While you won’t find it in official financial statements, most banks disclose this average somewhere near the front of their detailed annual reports.

    Cost to income ratio: Measures a bank’s operating expenses as a percentage of its total income. The lower the ratio, the better the bank is at controlling costs and most brokers prefer banks with a cost to income ratio of less than 50%.

    Bad debts ratio: Measures a bank’s provisioning for when a client can’t meet their repayments and a debt goes bad. The higher the number of bad loans, the higher you really want the net interest margin to be, otherwise it could wipe out a hefty chunk of profit.

    Return on assets: As a useful efficiency measure for banks, ROA indicates how profitable a bank is relative to its total assets. Calculated by dividing annual earnings by its total assets, ROA is displayed as a percentage – the higher the better – and should reveal how competent management is at using its assets, like mortgages to generate earnings.

    Tier 1 capital ratio: Is a litmus test of a bank’s capital strength. It’s arrived at by isolating the amount of ‘tier 1 capital’ – the highest quality capital – then identifying the proportion of ‘risk-weighted assets’. Capital ratios in the big four and Macquarie range between 10.8% and 12.2%.

    Price to book ratio: Is the value you would see if the business was liquidated and liabilities paid out. A ratio of 1 indicates shareholders can only expect a return of book value. A ratio above 1 indicates the extent to which shareholders are potentially exposed to market risk.

    Standout ASX bank shares to buy now

    Based on its forecasted pre-provision operating profit per share growth over the next 3 years, Goldman Sachs’ preferred major bank exposure is National Australia Bank Ltd (ASX: NAB). It expects NAB’s revenue momentum to remain superior to its peers, driven by its overweight exposure to SME lending. While NAB has taken the lowest provision for bad debts, at 0.38%, its credit impairment charge as a percentage of loans is also considerably lower than its peers.

    At a share price of $17.95, the bank is still trading 40% down on its 52-week high of $30.00. Goldman Sachs also reiterates a buy on Australia and New Zealand GrpLtd (ASX: ANZ) shares, which at $18.05 are still trading 38% down on their 52-week high of A$29.30.

    Based on its strong deposit franchise, Commonwealth Bank of Australia (ASX: CBA) is seen as more vulnerable to the medium-term impact of lower rates. The bank also has the highest exposure to more competitive mortgages relative to its peers. Based on a valuation that’s more expensive in relative and absolute terms, Goldman Sachs concludes that NAB and ANZ offer a more attractive entry point at current levels.

    Similarly, while Westpac Banking Corp (ASX: WBC) has demonstrated better expense control, stronger margins, and better than expected housing growth, the stock is not regarded as a buy. This is due to risk of higher investment spend, plus the risk of elevated fines and asset quality deterioration. At $17.36, Westpac shares are trading at a 42% discount to its 52-week high of $30.05.

    Market uncertainty over banks’ fortunes is reflected in buy, hold and sell consensus broker recommendations on ANZ, NAB and Westpac. However, brokers unanimously agree that Commonwealth Bank is not a buy, with 12 out of 15 seeing it as a strong sell.

    Despite the recent rally, bank share prices still suffer from a negative sentiment overhang that pre-dates COVID-19. Yet if the GFC is any proxy, the post-crisis period bodes well for the sector.

    For 5 more shares set for post-COVID-19 growth, don’t miss the free report below.

    NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

    Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

    One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

    Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%…

    Plus 3 more cheap bets that could position you to profit over the next 12 months!

    See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

    CLICK HERE FOR YOUR FREE REPORT!

    More reading

    Motley Fool contributor Mark Story has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post How to value the big four ASX banks appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2Mo7FGQ

  • Canopy Growth: Things Are Worse Than Thought, Says Jefferies

    Canopy Growth: Things Are Worse Than Thought, Says JefferiesWhat is the worst thing an investor could hear from a market share leader? According to Jefferies’ analyst Owen Bennett, it is probably the need to "understand what consumers want.”And that’s just what Canopy Growth (CGC) has said. According to the analyst, the Canadian cannabis producer’s disappointing FQ4 results indicate “things are worse than thought.”Canopy's Q4 net revenue came in at C$107.9 million, well below the C$128.9 million estimate and down by 13% from the previous quarter. The enormous overall net loss of C$1.3 billion, amounted to C$3.72 per share, far worse that the Street’s expectation of C$0.59 per share. Cue investors running to the exit door and a drop of 20% in the following trading session.Bennett recently upgraded Canopy’s rating from Sell to Hold, based on the reasoning “top line pressures were better understood,” and under the impression cost saving actions were moving the company in the right direction.Pointing out the slim bull case for Canopy rested on “increased focus on cost structure and profit delivery,” the analyst believes the turnaround appears more sluggish than anticipated as evidenced by operating expenses. Instead of improving, these increased by 17% compared to the previous quarter.Additionally, looking ahead, Canopy reduced expectations, describing FY21 as a “transition year,” and taking off the table previous forecasts for when it would achieve positive adjusted EBITDA.Along with the letdown of the report, the tone coming from Canopy’s direction has not impressed Bennett, who said, “While it said it is addressing certain headwinds with a shift into value and more high THC offerings, what really concerned us was commentary around needing to "understand what consumers want", and "servicing different segments". This is just basics and an issue we flagged over 12 months ago when initiating (Canopy having a catch all brand with no segmentation) and is something that in our view should be addressed prior to legalisation, not over a year into it, and especially from a market share leader.”To this end, Bennett reiterated a Hold and has a C$22.00 (US$16) price target on Canopy shares. (To watch Bennett’s track record, click here)Most of Wall Street echoes a neutral point of view, with TipRanks analytics exhibiting Canopy Growth as a Hold. Based on 15 analysts tracked by in the last 3 months, 2 say Buy, 10 suggest Hold, while 3 recommends Sell. Meanwhile the 12-month average price target stands at C$22.44, which aligns with where the stock is currently trading. (See Canopy Growth stock analysis on TipRanks)To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

    from Yahoo Finance https://ift.tt/36Ptd8M

  • Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

    Attention Biotech Investors: Mark Your Calendar For June PDUFA DatesDespite the FDA tied up with COVID-19-related activities, May turned out to be a positive month for biopharma companies from the perspective of drug approvals. Three new molecular entities were approved during the month and several other drugs also received the nod.Meanwhile, Blueprint Medicines Corp (NASDAQ: BPMC) faced disappointment at the FDA altar, as its NDA for avapritinib for treating fourth-line gastrointestinal stromal tumor was clamped with a complete response letter.Here are the key PDUFA dates scheduled for the unfolding month.Merck's Antibiotic Combo Up Before FDA For Label Expansion * Company: Merck & Co., Inc. (NYSE: MRK) * Type of Application: sNDA * Candidate: Recarbrio * Indication: hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia * Date: June 4Recarbrio is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a betalactamase inhibitor, indicated for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.Viela Eyes Commercial Status With its Autoimmune Disorder Drug Approval * Company: Viela Bio Inc (NASDAQ: VIE) * Type of Application: BLA * Candidate: inebilizumab * Indication: neuromyelitis optica spectrum disorder, or NMOSD * Date: June 11The FDA accepted the BLA for the investigational anti-CD19 monoclonal antibody on April 27, 2019. NMOSD is a rare autoimmune disease characterized by unpredictable attacks that often lead to severe, irreparable disability including blindness and paralysis.The company said in its first-quarter earnings release it has begun preparations for potential regulatory approval, hiring and training market access and sales teams and deploying MSLs. The company expects to commercialize the drug shortly after.Can Merck's Wonder Cancer Drug Snag Another Approval * Company: Merck * Type of Application: sBLA * Candidate: Keytruda * Indication: solid tumors * Date: June 16 * Merck announced April 7 FDA acceptance of the application with priority review. Keytruda as a monotherapy is being evaluated for treating adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high, as determined by an FDA-approved test, who have progressed following prior treatment and who have no satisfactory alternative treatment optionsUltragenyx Seeks Label Expansion For Partnered Drug To Treat Low Serum Phosphate Levels * Company: Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Kyowa Kirin * Type of Application: sBLA * Candidate: burosumab * Indication: hypophosphatemia * Date: June 18The FDA accepted the application for priority review Feb. 27. Burosumab is a fully human monoclonal IgG1 antibody, which works against the phosphaturic hormone FGF23. This hormone reduces serum levels of phosphorus and active vitamin D by regulating phosphate excretion and active vitamin D production by the kidney.It has already been approved for the treatment of X-linked hypophosphatemia in adult and pediatric patients 6 months of age and older. The companies are now seeking label expansion to include the indication FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.Epizyme Looks To Strike It Rich With Another Tazemetostat Approval * Company: Epizyme Inc (NASDAQ: EPZM) * Type of Application: sNDA * Candidate: tazemetostat * Indication: follicular lymphoma * Date: June 18Tazemetostat was initially approved for epithelioid sarcoma in January, and has been sold under the brand name Tazverik. The regulatory application, which was accepted for priority review, seeks approval for the drug for patients with relapsed or refractory follicular lymphoma who have received at least two prior lines of systemic therapy.Can Second Time Be Charm For Nabriva? * Company: Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) * Type of Application: NDA * Candidate: Contepo * Indication: complicated urinary tract infection or cUTI * Date: June 19Nabriva's original NDA was rejected by the FDA in April 2019, with the regulatory agency handing down a complete response letter on the pretext of issues related to facility inspections and manufacturing deficiencies at one of Nabriva's contract manufacturers.The company resubmitted the application in late December, and the FDA acknowledged the resubmission in mid-January.Evoke Knocks The FDA Altar After A Prior Rejection * Company: Evoke Pharma Inc (NASDAQ: EVOK) * Type of Application: NDA * Candidate: Gimoti * Indication: diabetic gastroparesis * Date: June 19Evoke faced a rejection at the FDA altar once, and resubmitted the application, which was accepted for review in January. GimotI is a nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.See also: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley Karyopharm Blood Cancer Drug On Track For Second Approval? * Company: Karyopharm Therapeutics Inc (NASDAQ: KPTI) * Type of Application: sNDA * Candidate: Selinexor * Indication: relapsed or refractory diffuse large B-cell lymphoma * Date: June 23Karyopharm announced on Feb. 19 FDA acceptance of the regulatory application, which sought accelerated approval for oral Selinexor tablets for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who have received at least two prior therapies.Selinexor was approved in July 2019 as a combo treatment option along with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma, who have received at least four prior therapies.Zogenix's Hopes For No Jitters On Seizure Drug Review * Company: Zogenix, Inc. (NASDAQ: ZGNX) * Type of Application: NDA * Candidate: Fintepla * Indication: seizures associated with Dravet syndrome * Date: June 25Zogenix's regulatory filing for Fintelpa was accepted for priority review in November 2019, with a PDUFA date of March 25. The FDA extended the review period by three months to give itself time to look at the additional data provided by the company.Heron Expects Gain From Pain Drug Review * Company: Heron Therapeutics Inc (NASDAQ: HRTX) * Type of Application: NDA * Candidate: HTX-011 * Indication: post-operative pain * Date: June 26Heron's HTX-011 is a combo drug consisting of bupivacaine and a low dose of non-steroidal anti-inflammatory drug meloxicam, and is a non-opioid pain drug. The NDA was originally submitted in October 2018, and in response to the application, the FDA issued a complete response letter in April 2019, citing the need for additional CMC and non-clinical information.Heron resubmitted the NDA in October 2019, and in February the company said the FDA extended the review period by three months, rendering the PDUFA data on June 26.If approved HTX-011 will compete with Pacira Biosciences Inc's (NASDAQ: PCRX) Exparel, Guggenheim Securities analyst Dana Flanders said in a recent note. Citing the firm's post-operative pain survey, Flanders said HTX-011 is likely to see significant growth at the expense of Exparel. The analyst said price point may be key in driving significant uptake.Can Chiasma Cross The FDA Hurdle This Time Around? * Company: Chiasma Inc (NASDAQ: CHMA) * Type of Application: NDA * Candidate: Mycapssa * Indication: acromegaly * Date: June 26The FDA accepted Chiasma's originally submitted NDA in August 2015.Mycapssa, or octreotide capsules, is an oral drug being evaluated for the maintenance therapy of adult patients with acromegaly. A complete response letter was issued by the FDA in April 2016, seeking an additional clinical trial to establish the efficacy. Following a resubmission in Dec. 2019, the FDA accepted the application in January, giving it a PDUFA date of June. 26.Acromegaly is a hormonal disorder that is caused by the production of too much hormone by the pituitary gland during adulthood, causing bone size to increase.Related Link: Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine DevelopmentIntercept's Wait For NASH Drug May Not End * Company: Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Type of Application: NDA * Candidate: Obeticholic acid * Indication: fibrosis due to non-alcoholic steatohepatitis * Date: June 26NASH has become a tough nut to crack for biotech companies, with no approved drug yet despite a plethora of ongoing research. Intercept filed the NDA in November 2019 following positive Phase 3 results from the GENERATE study. The PDUFA date, which was originally fixed as March 26, was extended by three months.However, dimming the prospects, the company informed earlier this month an Adcom meeting scheduled tentatively for June 9 was postponed by the FDA. The company, therefore, indicated the review period is likely to be extended.See more from Benzinga * The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight * The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2XUBsg1